The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 2, 2016, Pages 277-284

  Cohen, Robert ^a,b,c,d   Biscardi, Sandra ^a,c,d   Levy, Corinne ^a,b,c,d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b ACTIV   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d Groupe de Pathologie Infectieuse Pediatrique de la Societe Francaise de Pediatrie   (France)

Author keywords

acute otitis media; carriage; children; impact; invasive pneumococcal disease; Pneumococcal conjugate vaccine; pneumococcal meningitis; pneumonia

Indexed keywords

C REACTIVE PROTEIN; PNEUMOCOCCUS VACCINE; PROCALCITONIN; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; EMPYEMA; FRANCE; HEALTH CARE PLANNING; HUMAN; NONHUMAN; PLEURA EFFUSION; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; REVIEW; TREATMENT FAILURE; VACCINATION; ADOLESCENT; CHILD; HETEROZYGOTE; IMMUNOLOGY; INFANT; MENINGITIS, PNEUMOCOCCAL; MICROBIOLOGY; PNEUMONIA, PNEUMOCOCCAL; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; CARRIER STATE; CHILD; CHILD, PRESCHOOL; FRANCE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84960955637     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1116654     Document Type: Review

References (42)

1. W.A.de Steenhuijsen Piters, E.A.Sanders, D.Bogaert. The role of the local microbial ecosystem in respiratory health and disease. Philos Trans R Soc Lond B Biol Sci 2015; 370:1675; PMID:26150660; http://dx.doi.org/10.1098/rstb.2014.0294
2. P.Advisory Committee on Immunization. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35
3. P.Ter Horst, A.Jessen, S.Bogaerts, M.Spreen. [Clinical decision making with regard to the granting of escorted leave for forensic patients detained by court order in a Dutch psychiatric clinic. Role of gender, disorder and the type of offence in the procedure]. Tijdschr Psychiatr 2015; 57:314-22; PMID:26028011
4. E.Prina, O.T.Ranzani, A.Torres. Community-acquired pneumonia. Lancet 2015; 386:1097-108; PMID:26277247; http://dx.doi.org/10.1016/S0140-6736(15)60733-4
5. D.Scheifele, S.Halperin, L.Pelletier, J.Talbot. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis 2000; 31:58-64; PMID:10913397; http://dx.doi.org/10.1086/313923
6. W.P.Hausdorff, J.Bryant, P.R.Paradiso, G.R.Siber. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21; PMID:10619740; http://dx.doi.org/10.1086/313608
7. H.Goossens, M.Ferech, R.Vander Stichele, M.Elseviers, E.P.Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87; PMID:15708101; http://dx.doi.org/10.1016/S0140-6736(05)70799-6
8. J.H.Song, R.Dagan, K.P.Klugman, B.Fritzell. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012; 30:2728-37; PMID:22330126; http://dx.doi.org/10.1016/j.vaccine.2012.01.091
9. C.G.Whitney, M.M.Farley, J.Hadler, L.H.Harrison, N.M.Bennett, R.Lynfield, A.Reingold, P.R.Cieslak, T.Pilishvili, D.Jackson, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
10. R.Cohen, J.Gaudelus, O.Pexoito. Pneumococcal conjugate vaccine: estimation of target population. Medecine et Enfance 2005; 25:237-42
11. C.Levy, E.Varon, E.Bingen, A.Lecuyer, M.Boucherat, R.Cohen, G.Bacterial Meningitis Study. PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:168-70; PMID:21298818; http://dx.doi.org/10.1097/INF.0b013e3181f4cf69
12. J.Gaudelus, R.Cohen, J.Hovart. Evolution of PCV7 coverage in 2006 to 2008: analysis of health records. Medecine et Enfance 2009:151-4
13. A.Lepoutre, E.Varon, S.Georges, L.Gutmann, D.Levy-Bruhl. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008; 13:35; PMID:18761883
14. Anonymous. 2010. French vaccinal calendar recommendations. http://www.invs.sante.fr/beh/2010/14_15/beh_14_15pdf
15. A.Lepoutre, E.Varon, S.Georges, F.Dorleans, C.Janoir, L.Gutmann, D.Levy-Bruhl. Microbiologists of E, Networks ORP. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 33:359-66; PMID:25448105; http://dx.doi.org/10.1016/j.vaccine.2014.11.011
16. F.Angoulvant, C.Levy, E.Grimprel, E.Varon, M.Lorrot, S.Biscardi, P.Minodier, M.A.Dommergues, L.Hees, Y.Gillet, Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58:918-24; PMID:24532543; http://dx.doi.org/10.1093/cid/ciu006
17. E.Bingen, C.Levy, F.de la Rocque, M.Boucherat, E.Varon, J.M.Alonso, H.Dabernat, P.Reinert, Y.Aujard, R.Cohen, Bacterial meningitis in children: a French prospective study. Clin Infect Dis 2005; 41:1059-63; PMID:16142676; http://dx.doi.org/10.1086/432944
18. R.Cohen, C.Levy, E.Bingen, S.Bechet, V.Derkx, A.Werner, M.Koskas, E.Varon. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr 2012; 19:1132-9; PMID:22925540; http://dx.doi.org/10.1016/j.arcped.2012.07.013
19. R.Cohen, C.Levy, E.Bingen, M.Koskas, I.Nave, E.Varon. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301; PMID:22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
20. R.Cohen, C.Levy, E.Bonnet, S.Grondin, V.Desvignes, A.Lecuyer, B.Fritzell, E.Varon. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010; 28:6114-21; PMID:19490958; http://dx.doi.org/10.1016/j.vaccine.2009.05.037
21. R.Cohen, C.Levy, E.Bonnet, F.Thollot, M.Boucherat, B.Fritzell, V.Derkx, E.Bingen, E.Varon. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis 2011; 11:95; PMID:21501471; http://dx.doi.org/10.1186/1471-2334-11-95
22. R.Cohen, C.Levy, F.de La Rocque, N.Gelbert, A.Wollner, B.Fritzell, E.Bonnet, R.Tetelboum, E.Varon. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006; 25:1001-7; PMID:17072121; http://dx.doi.org/10.1097/01.inf.0000243163.85163.a8
23. R.Cohen, E.Varon, C.Doit, C.Schlemmer, O.Romain, F.Thollot, S.Bechet, S.Bonacorsi, C.Levy. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine 2015; 33:5118-26.
24. C.Godot, C.Levy, E.Varon, C.Picard, F.Madhi, R.Cohen. Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7 and 13 Valent Pneumococcal Conjugate Vaccination in Children in France. Pediatr Infect Dis J 2015; 34:e260-3; PMID:26181894; http://dx.doi.org/10.1097/INF.0000000000000818
25. C.Levy, E.Varon, S.Bechet, R.Cohen. Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in Children. Clin Infect Dis 2015; pii:civ692; [Epub ahead of print].
26. C.Levy, E.Varon, C.Picard, S.Bechet, A.Martinot, S.Bonacorsi, R.Cohen. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr Infect Dis J 2014; 33:1216-21; PMID:25037044; http://dx.doi.org/10.1097/INF.0000000000000451
27. C.Janoir, R.Cohen, C.Levy, E.Bingen, A.Lepoutre, L.Gutmann, E.Varon, Observatoires Regionaux du Pneumocoque n. Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France. PLoS One 2014; 9:e90935; PMID:24603763; http://dx.doi.org/10.1371/journal.pone.0090935
28. L.Caeymaex, E.Varon, C.Levy, S.Bechet, V.Derkx, V.Desvignes, C.Doit, R.Cohen. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014; 33:533-6; PMID:24263220; http://dx.doi.org/10.1097/INF.0000000000000213
29. V.Couloigner, C.Levy, M.Francois, P.Bidet, W.P.Hausdorff, T.Pascal, M.Boucherat, E.Bingen, P.Mariani, S.Pierrot, Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels. Pediatr Infect Dis J 2012; 31:154-8; PMID:21983212; http://dx.doi.org/10.1097/INF.0b013e3182357c8d
30. A.Perrocheau, A.Doyle, P.Bernillon, E.Varon, ORP, F.De La Rocque, R.Cohen, D.Levy Brülh. Evaluation of the surveillance of paediatric pneumococcal meningitis infections in France, 2001-2002 by capture-recapture method. Bull Epidemiol Hebd 2006; 2-3:16-8
31. R.Cohen, C.Levy, V.Hentgen, M.Boucherat, F.de La Rocque, P.d'Athis, E.Bingen. Relationship between clinical signs and symptoms and nasopharyngeal flora in acute otitis media. Clin Microbiol Infect 2006; 12:679-82; PMID:16774568; http://dx.doi.org/10.1111/j.1469-0691.2006.01483.x
32. J.L.Paradise. On classifying otitis media as suppurative or nonsuppurative, with a suggested clinical schema. J Pediatr 1987; 111:948-51; PMID:3681566; http://dx.doi.org/10.1016/S0022-3476(87)80226-3
33. R.Cohen, F.de la Rocque, M.Boucherat, C.Doit, E.Bingen, P.Geslin. Treatment failure in otitis media: an analysis. J Chemother 1994; 6 Suppl 4:17-22; discussion 3-4
34. D.Dupont, F.Mahjoub-Messai, M.Francois, C.Doit, P.Mariani-Kurkdjian, P.Bidet, S.Bonacorsi, A.Carol, E.Bingen. Evolving microbiology of complicated acute otitis media before and after introduction of the pneumococcal conjugate vaccine in France. Diagn Microbiol Infect Dis 2010; 68:89-92; PMID:20727478; http://dx.doi.org/10.1016/j.diagmicrobio.2010.04.012
35. C.Levy, M.François, P.Mariani-Kurkdjian, M.Boucherat, S.Béchet, E.Sobral, E.Varon, V.Couloigner, R.Cohen. Change in Pathogens implicated in Antibiotic Non Responsive Acute Otitis Media Before and After 13 Valent Pneumococcal Conjugate Vaccine Implementation in France Presented in part at 35th RICAI 2014. Available at http://www.ricai.fr/archives
36. M.Kempf, E.Varon, A.Lepoutre, A.Gravet, R.Baraduc, M.Brun, H.Chardon, J.Cremniter, J.Croize, F.Dalmay, Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network. Clin Microbiol Infect 2015; 21:35-42; PMID:25636925; http://dx.doi.org/10.1016/j.cmi.2014.08.009
37. L.Hall-Stoodley, F.Z.Hu, A.Gieseke, L.Nistico, D.Nguyen, J.Hayes, M.Forbes, D.P.Greenberg, B.Dice, A.Burrows, Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296:202-11; PMID:16835426; http://dx.doi.org/10.1001/jama.296.2.202
38. F.Mahjoub-Messai, C.Doit, J.L.Koeck, T.Billard, B.Evrard, P.Bidet, C.Hubans, J.Raymond, C.Levy, R.Cohen, Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children. J Clin Microbiol 2009; 47:837-40; PMID:19109482; http://dx.doi.org/10.1128/JCM.01547-08
39. J.A.Finkelstein, S.S.Huang, J.Daniel, S.L.Rifas-Shiman, K.Kleinman, D.Goldmann, S.I.Pelton, A.DeMaria, R.Platt. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics 2003; 112:862-9; PMID:14523178; http://dx.doi.org/10.1542/peds.112.4.862
40. R.Dagan, K.P.Klugman. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008; 8:785-95; PMID:19022193; http://dx.doi.org/10.1016/S1473-3099(08)70281-0
41. M.R.Moore, C.G.Whitney. Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program. Emerg Infect Dis 2015; 21:1551-6; PMID:26291238; http://dx.doi.org/10.3201/eid2109.150395
42. W.P.Hanage. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol 2008; 3:23-30; PMID:18230031; http://dx.doi.org/10.2217/17460913.3.1.23